Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotechs Benefit From Pharma Deals And Dollars

This article was originally published in Scrip

Executive Summary

Big pharma companies may be under pressure to buy like-sized peers with late-stage clinical programs and marketed products, but several collaborations with and investments in biotechnology firms announced during the first few days of 2016 show that the world's largest drug makers also are focused on long-term prospects for their research and development pipelines.

Advertisement

Related Content

Finance Watch: Former GSK CEO Witty, R&D Head Slaoui Join VC Firms
Deal Watch: Merck Digging Into Epigenetics With Proteros Partnership

Topics

Advertisement
UsernamePublicRestriction

Register

SC064139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel